

# Comparison of the Sensormedics® 3100A and Bronchotron® Transporter in a Neonatal Piglet ARDS Model

Stephen E. Messier, MD,\* Robert J. DiGeronimo, MD, and Robert K. Gillette, MD

**Summary.** The Sensormedics® 3100A (Cardinal Health, Dublin, OH) (HFOV) and the Bronchotron® (Percussionaire, Sandpoint, ID) (HFPV) are high-frequency ventilation devices used to support neonatal respiratory failure; however, a comparison of the devices, with respect to gas exchange at similar ventilator settings, has not been previously studied. Thus, we compared the ability of HFOV to that of HFPV to provide oxygenation and ventilation during acute lung injury in a newborn animal model. Using a saline lung lavage model, 12 neonatal piglets were randomized to initial support with either the HFOV or HFPV with settings adjusted to achieve PaCO<sub>2</sub> of 45–60 mmHg. After stabilization, ventilator settings and arterial blood gases were serially recorded for 30 min. Animals were then crossed over to the alternative device set to deliver the same V<sub>t</sub>, MAP, and F for an additional 30 min with the same parameters recorded. We found that the ΔP needed to generate adequate V<sub>t</sub> on HFPV (35 ± 7 cmH<sub>2</sub>O) trended higher versus HFOV (31 ± 7 cmH<sub>2</sub>O,  $P=0.09$ ) when the devices were matched for V<sub>t</sub>, F, and MAP. No significant differences in ventilation (PaCO<sub>2</sub> = 50 ± 10.7 mmHg vs. 46 ± 10 mmHg,  $P=0.22$ ) or oxygenation (PaO<sub>2</sub> = 150 ± 76 mmHg vs. 149 ± 107 mmHg,  $P=0.57$ ) between the devices were found. We conclude that HFPV ventilates and oxygenates as well as HFOV at equivalent ventilator settings. HFPV may require larger ΔP's to generate equivalent V<sub>t</sub>. **Pediatr Pulmonol.** 2009; 44:693–700. © 2009 Wiley-Liss, Inc.

**Key words:** high-frequency ventilation; high-frequency oscillatory ventilation; high-frequency percussive ventilation; tidal volume.

## INTRODUCTION

High-frequency ventilation (HFV) is commonly used to treat neonatal patients with respiratory failure as either primary therapy or rescue strategy following failure of conventional mechanical ventilation (CMV).<sup>1</sup> It is also commonly used for rescue therapy in older children and adults with severe hypoxic respiratory failure.<sup>2</sup> Common modes of HFV used in the United States are high-frequency oscillatory ventilation (HFOV) and high-frequency jet ventilation (HFJV).

Unfortunately, children whose care has escalated to HFV often cannot be safely converted back to CMV, and therefore are placed at significant risk of deterioration or death if transport is required.<sup>3,4</sup> HFOV has been shown in several studies to improve pulmonary outcomes in premature infants when used for initial ventilatory management of respiratory distress syndrome.<sup>5–9</sup> While HFOV is generally effective in improving oxygenation and ventilation, its utility in transport is limited because of its size, weight, and electromagnetic interference. Some case studies have described the use of HFJV in transport, but the bulkiness of the device makes it cumbersome for travel.<sup>10,11</sup> The Bronchotron® (Percussionaire, Sandpoint, ID) is a light, portable, pneumatically powered,

Division of Neonatology, Department of Pediatrics, Wilford Hall Medical Center, Lackland AFB, Texas.

Presented as a poster at the Society of Pediatric Research Meeting, Honolulu, HI, May 2008.

Presented as a platform at the 25th High Frequency Ventilation Meeting, Snowbird, UT, March 2008.

The views and opinions expressed in this manuscript are those of the authors and do not reflect the official policy or position of the Air Force Medical Department, Department of the Air Force, Department of Defense, or the United States Government.

Percussionaire® (Sandpoint, ID) Corporation provided a loaner Bronchotron® for use in this study. Percussionaire® had no input or influence on the contents of this article.

\*Correspondence to: Stephen E. Messier, MD, US Naval Hospital—Okinawa, PSC 482, Box 2640, FPO, AP 96362.

E-mail: stephen.messier@med.navy.mil

Received 2 September 2008; Revised 2 March 2009; Accepted 2 March 2009.

DOI 10.1002/ppul.21041

Published online 4 June 2009 in Wiley InterScience (www.interscience.wiley.com).

pressure-limited, time-cycled, high-frequency percussive ventilator (HFPV) which is gaining favor in a number of centers for intrahospital and interhospital transport of neonates. One center recently reported their experience of 134 infants in whom 96% were successfully transported using HFPV with improvement in oxygenation, ventilation, and acid–base status during the time that the patients were on the transport ventilator.<sup>12</sup>

We are unaware of any studies comparing the gas exchange of HFOV to HFPV. Anecdotal transport experience led us to believe that HFPV was more efficient in gas exchange than HFOV. There is also limited data on the comparison of gas exchange at different levels of mean airway pressure (MAP) on HFOV or HFPV. Therefore, a randomized, controlled crossover study using a neonatal porcine lung injury model was performed to determine whether gas exchange was similar between the Bronchotron<sup>®</sup> HFPV and the Sensormedics<sup>®</sup> 3100A (Cardinal Health, Dublin, OH) HFOV when the devices were matched for tidal volume ( $V_t$ ), frequency (F), fraction of inspired oxygen ( $FiO_2$ ), and MAP and to determine whether gas exchange on each ventilator was different at two different levels of MAP.

## MATERIALS AND METHODS

All procedures were carried out according to a protocol approved by the Wilford Hall Medical Center Institutional Animal Care and Use Committee.

### Materials

#### Lung Injury Model

Fifteen-term gestation, 3- to 5-day-old, unweaned Yorkshire neonatal piglets (mean weight: 4 kg, range

3.0–5.0 kg) were used. Each study piglet was initially anesthetized with isoflurane (3.5–4.5%), intubated with a 3.5 cuffed endotracheal tube (ETT) placed under a radiant warmer and conventionally ventilated. Femoral venous and arterial catheters were placed for access and arterial blood gas analysis, respectively. Continuous sedation and paralysis were provided with fentanyl (45–90 mcg/kg/hr) and pancuronium (0.1–0.3 mg/kg/hr) infusions, respectively. Lung injury was produced with saline lavage (8 ml/kg dwells for 30 sec). Saline dwells were continued until arterial  $PaO_2$  decreased below 60 mmHg on  $FiO_2$  of 1.0 (average  $15 \pm 7$  dwells per study animal). Between each dwell, injury was also induced with volutrauma and atelectatruama using the MVP-10 IMV ventilator (Cardinal Health) for 1–3 min with the following settings: PIP 13–20 cmH<sub>2</sub>O, PEEP 0–5 cmH<sub>2</sub>O, I-Time 0.35 sec, E-Time 0.65–1.7 sec, (RR 30–60) flow 8 lpm, and  $FiO_2$  1.0 ( $V_t = 10.3 \pm 2.1$  ml/kg). Attempts were made to keep the MVP-10 settings constant, making no adjustment for  $PaCO_2$ , but the ventilator settings occasionally needed to be adjusted in order to resuscitate the pig after saline lavage.

#### MVP 10 (Cardinal Health)


The MVP-10 is a pneumatically driven conventional mechanical ventilator used for conventional transport of neonates. It has the ability to generate CPAP or IMV breaths and has the following parameters: flow rate, PIP, PEEP, I-time, E-time, and  $FiO_2$ .

#### Bronchotron<sup>®</sup> (Percussionaire) (Fig. 1)

The Bronchotron<sup>®</sup> is a pneumatically powered, pressure-limited, time-cycled, HFPV that was developed in the mid-1980s by Dr. Forrest Bird. The ventilator has an internal pneumatic timing cartridge which cycles high-pressure gas supply at a frequency of 3–10 Hz. Rate and amplitude are adjustable while the I-time is not, instead being dependent on the resistance and compliance of the respiratory system as well as the set breath rate. The high-frequency output pulses from the timing cartridge then enter a sliding piston mechanism through a venturi cavity in its central axis (Phasitron<sup>®</sup>) (Percussionaire). This piston/venturi acts as an inspiratory and expiratory valve. In the inspiratory phase, the pulse of gas is augmented by additional entrained gas proportional to the pressure difference before and after the venturi.<sup>13</sup> This mechanism limits the tidal volumes seen by the neonatal lungs which can be a cause of ventilator-induced lung injury.<sup>14,15</sup> During expiration (between pulses from the timing cartridge), there is no gas inflow or entrainment, the piston springs back opening an exhalation port, and gas is allowed to exit the patient through an adjustable resistor that provides PEEP. The device uses 12 lpm of gas flow. The ventilator can be used in CMV mode, high-frequency

#### ABBREVIATIONS

ABG	Arterial blood gas
ARDS	Acute respiratory distress syndrome
C	Compliance
CMV	Conventional mechanical ventilation
$\Delta P$	Proximal pressure amplitude
F	Frequency
$FiO_2$	Fraction of inspired oxygen
HFOV	High-frequency oscillatory ventilation
HFPV	High-frequency percussive ventilation
HFV	High-frequency ventilation
IMV	Intermittent mandatory ventilation
MAP	Mean airway pressure
MVI	Modified Ventilatory Index
OI	Oxygenation Index
PEEP	Positive end expiratory pressure
PIP	Peak inspiratory pressure
$PaCO_2$	Arterial partial pressure of carbon dioxide
$PaO_2$	Arterial partial pressure of oxygen
R	Resistance
RR	Respiratory rate
$V_t$	Tidal volume



**Fig. 1.** The Bronchotron<sup>®</sup> HFPV. The percussion knob primarily sets the breath frequency and the flowrate knob primarily sets breath size; however, adjusting either knob can affect both parameters. The Phasitron<sup>®</sup> acts as a pneumatic clutch for the breaths coming from the Bronchotron<sup>®</sup>. It has an inspiratory valve and a PEEP valve. The ETT fits on the right hand side of the Phasitron<sup>®</sup>.

mode, or a combination of the two (high frequency with IMV sigh breaths); however, it was used only in high-frequency mode in our experiment as it is often used in that way for neonatal transports and that was our particular study interest. On the face of the ventilator, there is an operational pressure dial which was set at 35 psi during the experiment, a flowrate dial, which adjusts the gas flow to the Phasitron<sup>®</sup> thus affecting the pulse amplitude, and a “Percussion” dial, which adjusts the rate of the oscillations. An adjustable PEEP valve is located on the Phasitron<sup>®</sup> body itself and is used to set the MAP.

#### Sensormedics 3100A (Cardinal Health)

The 3100A is a high-frequency oscillatory ventilator developed in the early 1980s. It uses an electromagnetically driven piston to change the volume, and thus the pressure inside of a rigid circuit containing a continuous bias flow of fresh gas. By this mechanism, small tidal volume breaths are sent into the patient's lungs. It runs exclusively in high-frequency mode. It delivers pressure-limited, time-cycled breaths at a rate of 3–15 Hz. The following parameters were adjusted during these experiments: MAP,  $\Delta P$ , and Hz. The I:E ratio and bias flow, while adjustable, were set at 33% and 20 lpm, respectively.

#### Florian<sup>®</sup> Neonatal Respiratory Monitor (Acutronic<sup>®</sup> Medical Systems, Zug, Switzerland)

The Florian<sup>®</sup> has a hot wire anemometer that measures airflow, which is mathematically integrated by an internal algorithm to give measured tidal volume. It also has an internal pressure transducer. It operates in both conventional and high-frequency mode and has a sampling rate of 1 kHz. Pressure measurements (PIP, MAP, and PEEP) are recorded in both conventional and high-frequency mode to a 1 cmH<sub>2</sub>O precision. We calculated  $\Delta P$  from these values as PIP – PEEP.  $V_t$  is measured to a 0.1 ml precision.<sup>16</sup> We measured  $V_t$  just proximal to the ETT.

MAP and  $\Delta P$  were measured through a side port ETT adapter, so that consistency in the parameters' measurement between each ventilator would be preserved. Pulmonary mechanics (respiratory system R and dynamic compliance C) are internally calculated by the device in CMV mode from flow and pressure inputs.

#### Experimental Procedure

After intubation and instrumentation as described above, the respiratory system (lung and ETT tube) R and C were measured at baseline ( $t_0$ ) (Table 1). Lung injury was induced as described above. After target lung injury was obtained (mean time to injury  $93 \pm 37$  min), R and C values were again measured ( $t_1$ ) and piglets were assigned to their initial study mode of HFV (either HFPV or HFOV) ( $t_2$ ). The first high-frequency ventilator was initially set to a rate of 6–8 Hz to facilitate matching frequency on both ventilators, a MAP of 0–2 cmH<sub>2</sub>O above the MAP on the MVP-10 and a  $V_t$  of 2–3 ml/kg with good chest wall vibration. These initial settings were determined to give blood gas values that were close to our goals during pilot animal experiments prior to commencing this study. Settings were further adjusted to give PaCO<sub>2</sub> values between 45 and 60 mmHg, and PaO<sub>2</sub> values between 60 and 80 mmHg on FiO<sub>2</sub> = 1.0. After achieving the goal blood gas values, ventilation was continued without further adjustment of the high-frequency ventilator for 10 min to ensure stability of the blood gases ( $t_3$ ), after which ventilatory parameters (MAP, PIP, PEEP,  $V_t$ , and F) and ABGs were recorded every 5 min until six ABGs were obtained. Piglets were then briefly placed back on the MVP-10 and the respiratory systems R and C were again measured ( $t_4$ ). Animals were converted to the secondary high-frequency ventilator and settings were adjusted to achieve the same MAP,  $V_t$ , and F as on the first HFV ( $t_5$ ). Animals were allowed to stabilize for 10 min on this new ventilator and then ventilatory parameters (MAP, PIP,

TABLE 1—Schematic of Experimental Procedure

		Piglet intubated, instrumented and sedated
Run 1	t0	Start MVP-10. Baseline R and C measured. Saline lavage started
	t1	Target injury achieved. Repeat R and C measurements.
	t2	Start HFV #1
	t3	Target settings achieved and stable for 10 minutes
		Measurements every 5 minutes for 25 minutes
	t4	Change to MVP-10. Repeat R and C measurements
	t5	Start HFV #2 at same Vt, MAP, and F as HFV #1 and stabilize for 10 minutes
Run 2		Measurements every 5 minutes for 25 minutes
	t6	Change to MVP-10. Repeat R and C measurements
	t7	Increase MAP by 5 cmH <sub>2</sub> O and Start HFV#1
	t8	Target settings achieved and stable for 10 min
		Measurements every 5 minutes for 25 minutes
	t9	Change to MVP-10. Repeat R and C measurements
	t10	Start HFV #2 at same Vt, MAP, and F as HFV #1 and stabilize for 10 minutes
		Measurements every 5 minutes for 25 minutes
	t11	Change to MVP-10. Repeat R and C measurements
	t12	Euthanize pigs and perform gross and microscopic pathology on lungs

PEEP, V<sub>t</sub>, and F) and ABGs were again recorded every 5 min until six ABGs were obtained. The piglet was then placed back on the MVP-10 and the respiratory systems R and C were again measured (t<sub>6</sub>) (Run 1).

Next, in order to look at changes in gas exchange at a higher MAP, the piglets were put back on the first high-frequency ventilator and the MAP increased by

5 cmH<sub>2</sub>O in an attempt to further recruit the lung (t<sub>7</sub>). The ventilator settings were adjusted to closely match the V<sub>t</sub> and F settings from Run 1. Ventilation was continued on these settings for 10 min (t<sub>8</sub>) after which ventilatory parameters (MAP, PIP, PEEP, V<sub>t</sub>, and F) and ABGs were again recorded every 5 min until six ABGs were obtained. Piglets were then briefly placed back on the MVP-10 for the measurement of respiratory systems R and C (t<sub>9</sub>). Animals were then converted back to the secondary high-frequency ventilator at the same, V<sub>t</sub>, and F (t<sub>10</sub>). Animals were allowed to stabilize for 10 min on the second ventilator and then ventilatory parameters (MAP, PIP, PEEP, V<sub>t</sub>, and F) and ABGs were again recorded every 5 min until six ABGs were obtained. The piglet was finally placed back on the MVP-10 and the respiratory systems R and C were measured once more (t<sub>11</sub>). At the end of the protocol, all piglets were euthanized and the lungs harvested for gross and microscopic evaluation to determine for extent of lung injury.

**Statistics**

The ventilators were randomized as to which HFV was used first to eliminate starting order as a confounder, but the data were analyzed by device regardless of order of use to determine if there was a statistically significant difference in the ability of the two devices to ventilate at equivalent settings. All statistics are reported as mean and SD. Primary outcomes were PaCO<sub>2</sub> and PaO<sub>2</sub> comparing the ventilators at each MAP level. Secondary outcomes were comparing the gas exchange of each ventilator at the different MAP levels, and comparing the ΔP required to generate equal V<sub>t</sub> between ventilators at each MAP level and between MAP levels for each ventilator. Post hoc analysis compared PaO<sub>2</sub> over the six time points of the initially randomized HFV run only, comparing the six animals started on each HFV, reflecting rapidity of recruitment. A repeated measures analysis of variance was used to determine differences in outcome variables (PaCO<sub>2</sub>, PaO<sub>2</sub>, V<sub>t</sub>, ΔP) over time. Power analysis determined a sample size of 12, provided 80% power to detect a 2 SD difference between groups, from baseline to end of study at the alpha level of 0.05.

**RESULTS**

Twelve piglets were included in the data analysis. Three animals were excluded including two piglets that died during induction of lung injury and one that failed to achieve target blood gas parameters.

**Lung Injury**

Significant lung injury was produced in all study animals as demonstrated by changes in R and C values, OI, and MVI pre- and post-saline lavage (Table 2). Lung C and



TABLE 2—Lung Injury Data, Mean (SD)

	Pre-lavage	Post-lavage	After Run 1	After Run 2
All animals				
C (ml/cmH <sub>2</sub> O)	2.4 (0.6)	0.9 (0.3)	1.3 (0.8)	1.8 (0.5)
R (cmH <sub>2</sub> O/L/sec)	113 (13)	156 (33)	143 (32)	128 (17)
OI	1.4 (0.8)	10.7 (4.0)		
MVI	30 (13)	109 (34)		
Bronchotron as first high-frequency device				
C (ml/cmH <sub>2</sub> O)	2.3 (0.7)	1.0 (0.2)	1.5 (1.0)	1.7 (0.4)
R (cmH <sub>2</sub> O/L/sec)	107.5 (15.6)	147 (26.1)	136 (35)	123 (19)
OI	1.4 (0.9)	9.8 (3.8)		
MVI	30 (17)	106 (24)		
3100A as first high-frequency device				
C (ml/cmH <sub>2</sub> O)	2.6 (0.5)	1.0 (0.4)	1.2 (0.6)	1.8 (0.6)
R (cmH <sub>2</sub> O/L/sec)	118 (7)	162 (40)	151 (31)	133 (16)
OI	1.5 (0.7)	11.5 (4.2)		
MVI	30 (10)	112 (44)		

OI = (MAP)(FiO<sub>2</sub>)/(PaO<sub>2</sub>); MVI = [(PIP)(rate)(PaCO<sub>2</sub>)]/1000.

R did not significantly change during Run 1. While R and C did improve with the increase in MAP between Run 1 and Run 2, the respiratory system was stable within clinically relevant ranges throughout Run 2 (Table 2). Additionally, there were no statistically significant differences between the matched MAP, V<sub>t</sub>, and F settings between the different runs (Table 3 and Fig. 2). All animals had histological evidence of alveolar lung injury (hyaline membranes, intra-alveolar, and interseptal edema at necropsy).

### PaCO<sub>2</sub> and PaO<sub>2</sub> Difference Between 3100A and Bronchotron® (Fig. 3)

For Run 1, at lower MAP, the mean PaCO<sub>2</sub> after 30 min on the Bronchotron® at stable settings was 49.7 ± 10.7 mmHg versus 45.5 ± 10.0 mmHg with the 3100A (*P* = 0.22). For Run 2, at higher MAP, the mean PaCO<sub>2</sub> after 30 min on the Bronchotron® with stable settings was 49.6 ± 11.1 mmHg vs. 46.8 ± 11.7 mmHg with the 3100A (*P* = 0.33). Similarly, the mean PaO<sub>2</sub> during Run 1, after 30 min on the Bronchotron® at stable settings, was 150 ± 76 mmHg vs. 149 ± 107 mmHg with the 3100A (*P* = 0.57). For Run 2, the mean PaO<sub>2</sub> with the Bronchotron® was 311 ± 125 mmHg vs. 297 ± 128 mmHg with the 3100A (*P* = 0.99). Comparing each ventilator to itself between runs (i.e., keeping V<sub>t</sub> and

frequency the same, but increasing the MAP by 5 cmH<sub>2</sub>O), there was a significant change in the PaO<sub>2</sub> on both the Bronchotron (*P* = 0.001) and the 3100A (*P* = 0.0004), but there was no significant difference in the PaCO<sub>2</sub> on either the Bronchotron (*P* = 1.0) or the 3100A (*P* = 0.64).

### Analysis of ΔP Needed to Produce Similar V<sub>t</sub>

We looked at what ΔP was needed on each ventilator to achieve similar V<sub>t</sub> during the experiment (Fig. 3). For Run 1, mean ΔP on the Bronchotron® and the 3100A were 35 ± 7 cmH<sub>2</sub>O versus 31 ± 7 cmH<sub>2</sub>O, respectively (*P* = 0.09). For Run 2, mean ΔP on the Bronchotron® and the 3100A was 36 ± 3 cmH<sub>2</sub>O vs. 32 ± 3 cmH<sub>2</sub>O, respectively (*P* = 0.10). Furthermore, there was no significant difference in the ΔP needed to generate V<sub>t</sub> from Run 1 to Run 2 on the Bronchotron (*P* = 0.78) or on the 3100A (*P* = 0.27).

### Post Hoc Analysis of Rapidity of Oxygenation Improvement

Looking at only the first set of six time points of the six animals initially randomized to HFOV versus the six randomized to HFPV, mean PaO<sub>2</sub> at time point 1 was 79 ± 32 vs. 125 ± 58, respectively (*P* = 0.13) while at time point 6 it was 81 ± 28 versus 184 ± 75, respectively (*P* = 0.01). The interaction of time versus

TABLE 3—Matched Ventilator Parameters, Mean (SD)

	Run 1			Run 2		
	Bronchotron	3100A	<i>P</i> -value	Bronchotron	3100A	<i>P</i> -value
TV (ml/kg)	3.1 (0.8)	3.0 (0.7)	0.87	3.1 (0.7)	3.0 (0.6)	0.82
F (Hz)	7.2 (0.6)	7.2 (0.6)	0.97	7.2 (0.6)	7.3 (0.6)	0.90
MAP (cmH <sub>2</sub> O)	8.5 (1.6)	8.4 (1.6)	0.88	13.6 (2.3)	13.6 (2.2)	0.98




Fig. 2. Matched parameters on each ventilator for each of 12 subjects. Values for Bronchotron (black) and 3100A (white). Run 1 displayed on the left and Run 2 on the right.

device was significant by repeated measures ANOVA ( $P = 0.0003$ ) indicating that oxygenation improved more rapidly on HFPV than on HFOV during each animal's first half an hour on HFV after lung injury.

## DISCUSSION

When matched for  $V_t$ ,  $F$ , and MAP in a neonatal ARDS piglet lung injury model, we have shown that the HFPV and HFOV devices ventilate and oxygenate within comparable clinical parameters. Also, while oxygenation improved when the MAP increased (from Run 1 to Run 2) on each device, ventilation did not change for the same  $V_t$  and  $F$ . The improvement in oxygenation is presumably due to improved lung recruitment and decreased  $V/Q$  mismatch. The equivalence of ventilation between the two devices is consistent with the notion that  $\text{CO}_2$  elimination during HFV is dependent only on  $V_t$  and  $F$  regardless of the mode of HFV or the MAP.<sup>9,17</sup> We are not aware of any other head-to-head animal studies comparing these two modes of HFV.

While HFOV has been studied in a number of different animal lung injury models, there are few relevant animal studies on HFPV. Of the studies that have been done, only larger animals have been used simulating adult ARDS and burn injury.<sup>18</sup> There have not been studies published to date using small animals more relevant to pediatric and neonatal lung injury. Additionally, the majority of human clinical studies done on HFPV have been case series involving pediatric and adult patients comparing it with conventional ventilation.<sup>18</sup> However, despite this lack of




Fig. 3. Mean and SD of  $\text{PaCO}_2$ ,  $\text{PaO}_2$ , and  $\Delta P$  at time 6 for all study animals separated by ventilator and by run.

evidence, some have suggested that HFPV has become the standard of care at burn centers in the United States.<sup>19</sup> A randomized clinical trial involving eight infants done in 1988 comparing pressure volume curves on CMV to HFPV concluded that HFPV provides better sustained lung recruitment than CMV.<sup>20</sup> There has been one animal study comparing CMV, HFOV, and HFPV. This study concluded that HFPV use resulted in significantly less lung damage than either CMV or HFOV in an adult baboon model of smoke inhalational injury.<sup>21</sup>

In our study, we chose to match  $V_t$  instead of  $\Delta P$ , as this is more consistent with the physiology of gas exchange in HFV as noted above. Matching  $F$  and  $V_t$  equalizes the confounding variables and allows a conclusion that any difference in  $\text{PaCO}_2$  must be due to ventilator differences. While the I:E ratios of the two devices are unable to

be matched, prior study has demonstrated that different I:E ratios did not change  $\text{CO}_2$  elimination when  $V_t$  and  $F$  were controlled for.<sup>22,23</sup> Thus, the lack of a detectable difference in  $\text{PaCO}_2$  implies the ventilators provide equivalent gas exchange. While many providers in a clinical setting will adjust the  $\Delta P$  according to the visible oscillations of the patient's chest as a surrogate for  $V_t$ , we know that the relationship between  $V_t$  and  $\Delta P$  is dependent on lung resistance and compliance (i.e., degree of illness) as well as the internal resistance and compliance of the ventilator circuit. For example, we noted that a Bronchotron<sup>®</sup>  $V_t$  of 2.5 cc/kg required a  $\Delta P$  from 22 to 43 mmHg with similar ranges for the 3100A. Animal and test lung studies<sup>24,25</sup> comparing performance characteristics of various high-frequency ventilators have shown that, as well as changing with degree of illness, the relationship between  $V_t$  and  $\Delta P$  also varies between HFV types when matched for lung resistance and compliance. If so, matching  $\Delta P$  provided by different modes of HFV would not be equivalent to matching  $V_t$  ( $V_t$  has to be matched directly). In our study, we did observe a trend toward requiring a larger  $\Delta P$  with the Bronchotron<sup>®</sup> to deliver the same  $V_t$  as the 3100A, and although not statistically significant, this concept deserves further study. We believe based on the studies<sup>24,25</sup> noted that this is a real effect but our study was not powered so as to overcome the confounding variation in  $R$  and  $C$  (affecting  $\Delta P$  vs.  $V_t$ ), which were matched between devices within each animal but varied widely between animals. We speculate the effect is due to differences in ventilator pressure waveforms, inspiratory times, and operating mechanisms.

The introduction of  $V_t$  measurements in CMV in recent years has contributed greatly to safe and effective patient management. Likewise, since HFV  $\Delta P$  does not uniquely determine  $V_t$ , targeting volume during HFV could be expected to similarly improve ventilator management by limiting the  $V_t$  and thus decreasing the risks of hyper-ventilation in ELBW infants and by allowing rational choice of  $\Delta P$  and  $F$  setting combinations to minimize volutrauma and avoid gas trapping. Air flow and volume measurements may also help detect and respond to  $R$  and  $C$  changes to the patient-ventilator system caused by clinical deterioration or improvement, ETT dislodgement or obstruction, surfactant administration, etc. However, measurement of  $V_t$  during HFV is much more challenging due to the small volumes involved and the rapid changes in airflow that occur during HFV. It has been recently reported in an observational study using a hot wire anemometer that  $V_t$ 's of 1.6–1.8 ml/kg were needed to maintain normocapnia in premature infants ventilated at frequencies of 10–15 Hz.<sup>26</sup> Further development of routine clinical HFV  $V_t$  measurement is clearly warranted to enhance the safety and utility of these devices.

In CMV, the dependence of minute ventilation on  $V_t$  and rate but not MAP, and the effect of MAP on lung volume,

lung resistance, and compliance, and thus on the relationship of  $V_t$  to  $\Delta P$  are well understood. The effects of similar parameters in HFV have not been studied extensively. An early study<sup>27</sup> found that  $\text{CO}_2$  elimination is similar at varying levels of MAP when  $V_t$  and  $F$  are held constant, using an experimental high-frequency device in a dog model. Equivalent results were found in normal and saline lavaged rabbits.<sup>28</sup> Similarly, our results with clinical HFV's showed that with  $V_t$  and  $F$  held constant, increasing MAP by 5 cmH<sub>2</sub>O did not affect  $\text{PaCO}_2$  levels for either ventilator. This again suggests that ventilation depends only on  $V_t$  and  $F$ , and not on MAP or type of HFV, although we did not test a sufficient range of MAP levels to exhaustively address this issue.

Theoretically, increasing HFV MAP and thus lung recruitment might be expected to change both lung  $R$  and  $C$  and therefore the relationship between  $V_t$  and  $\Delta P$ , much as it does in CMV by changing the position on the compliance curve. Thus, clinically one might expect a change in  $\text{PaCO}_2$  with increased MAP at the same  $\Delta P$  setting. However, a human neonatal study<sup>29</sup> indicated that  $V_t$  measured with a pneumotachograph did not change when MAP was increased by 2 and then 5 cmH<sub>2</sub>O at fixed  $\Delta P$  in each infant. In contrast, the previously mentioned observational neonatal study<sup>24</sup> showed a significant positive association by multiple regression between MAP and  $V_t$  in patients managed clinically for normocapnia, not controlling for  $\Delta P$ . Our study found no difference in  $\Delta P$  at fixed  $V_t$  between two MAP levels for either HFV. We noted, however, that changing MAP in our model unexpectedly resulted in only small effects on respiratory systems  $R$  and  $C$ , so that any resulting effect on  $\Delta P$  might not have been detectable. While a larger change in MAP may have resulted in a detectable change in both the previous study<sup>29</sup> and ours, we did not answer this question with our model. This important issue also deserves further study.

In conclusion, when matched for  $V_t$ ,  $F$ , and MAP, the Bronchotron<sup>®</sup> and the Sensormedics<sup>®</sup> 3100A appear to be equally effective in ventilating and oxygenating a newborn piglet with ARDS. Increasing MAP on either ventilator increases  $\text{PaO}_2$  but does not seem to have an affect on ventilation. Post hoc analysis leads us to hypothesize that HFPV may recruit the lung faster than HFOV. We believe that further investigation into comparison of different modes of HFV (i.e., HFOV, HFJV, and HFPV) in animals with higher OIs as well as the clinical utility of  $V_t$  measurement during HFV is warranted.

## ACKNOWLEDGMENTS

We would like to thank Dr. Anneke Bush ScD, MHS, epidemiologist/biostatistician, for her help with the statistical analysis of our data and Maj. Jerry Cowart DVM for his help with obtaining and interpreting the histological specimens collected.

## REFERENCES

- Henderson-Smart DJ, Cools F, Bhuta T, Offringa M. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in premature infants. *Cochrane Database Syst Rev* 2007;3:CD0000104.
- Ventre KM, Arnold JH. High frequency oscillatory ventilation in acute respiratory failure. *Paediatr Resp Rev* 2004;5:323–332.
- Boedy RF, Howell CG, Kanto WP. Hidden mortality rate associated with extracorporeal membrane oxygenation. *J Pediatr* 1990;117:462–464.
- DiGeronimo RJ, Henderson CL, Grubb PH. Referral and transport of ECMO patients. In: van Meurs K, Lally KP, Peek G, Zwischenberger JB, editors. *ECMO: Extracorporeal cardiopulmonary support in critical care*, 3rd edition. Ann Arbor, MI: Extracorporeal Life Support Organization; 2005. pp. 157–162.
- Clark RH, Gerstmann DR, Null DM, deLemos RA. Prospective randomized comparison of high frequency oscillatory and conventional ventilation in respiratory distress syndrome. *Pediatrics* 1991;89:5–12.
- HiFO Study Group. Randomized study of high-frequency oscillatory ventilation in infants with severe respiratory distress syndrome. *J Pediatr* 1993;122:609–619.
- Gerstmann DR, Minton SD, Stoddard RA, Meredith KS, Monaco F, Bertrand JM, Battisti O, Lanhendries JP, Francois A, Clark R. The Provo multicenter early high-frequency oscillatory ventilation trial: Improved pulmonary and clinical outcome in respiratory distress syndrome. *Pediatrics* 1996;98:1044–1057.
- Plavka R, Kopecky P, Sebron V, Svihovec P, Zlatohlavkova B, Janus V. A prospective randomized comparison of conventional mechanical ventilation and very early high frequency oscillatory ventilation in extremely premature newborns with respiratory distress syndrome. *Intensive Care Med* 1999;25:68–75.
- Keszler M. High frequency ventilation: Evidence based practice and specific clinical indications. *NeoReviews* 2006;7:e234–e249.
- Scuderi J, Elton CB, Elton DR. A cart to provide high frequency jet ventilation during transport of neonates. *Respir Care* 1992;37:129–136.
- Mainali ES, Greene C, Rozycki HJ, Gutcher GR. Safety and efficacy of high frequency jet ventilation in transport. *J Perinatol* 2007;28:609–613.
- Honey G, Bleak T, Karp T, MacRitchie A, Null D. Use of the Duotron transporter high frequency ventilator during neonatal transport. *Neonatal Netw* 2007;26:167–174.
- Percussionaire Corporation. *Bronchotron—I. Users Guide*. Percussionaire Corporation; Sandpoint, ID, 2003.
- Clark RH, Gerstmann DR, Jobe AH, Moffitt ST, Slutsky AS, Yoder BA. Lung injury in neonates: Causes, strategies for prevention, and long-term consequences. *J Pediatr* 2001;139:478–486.
- Villar J, Kacmarek RM, Hedenstierna G. From ventilator-induced lung injury to physician-induced lung injury: Why the reluctance to use small tidal volumes? *Acta Anaesthesiol Scand* 2004;48:267–271.
- Scafarro P, Pillow JJ, Sly PD, Cotting J. Reliable tidal volume estimates at the airway opening with an infant monitor during high frequency oscillatory ventilation. *Crit Care Med* 2001;29:1925–1930.
- Cronin J. High frequency ventilator therapy for newborns. *J Intensive Care Med* 1994;9:71–85.
- Salim A, Martin M. High frequency percussive ventilation. *Crit Care Med* 2005;33:S241–S245.
- Paulsen SM, Killyon GW, Barillo DJ. High frequency percussive ventilation as a salvage modality in adult respiratory distress syndrome: A preliminary study. *Am Surg* 2002;68:852–856.
- Pfeninger J, Minder C. Pressure-volume curves, static compliances and gas exchange in hyaline membrane disease during conventional mechanical and high-frequency ventilation. *Intensive Care Med* 1988;14:364–372.
- Cioffi WG, deLemos RA, Coalson JJ, Gerstmann DA, Pruitt BA. Decreased pulmonary damage in primates with inhalation injury treated with high frequency ventilation. *Ann Surg* 1993;218:328–337.
- Courtney SE, Weber KE, Spohn WA, Bender CV, Malin SW, Gotshall RW. Cardiorespiratory effects of changing inspiratory to expiratory ratio during high-frequency oscillation in an animal model of respiratory failure. *Pediatr Pulmonol* 1992;13:113–116.
- Yamada Y, Hales CA, Vengas JG. Inspiratory to expiratory time ratio and alveolar ventilation during high frequency ventilation in dogs. *J Appl Physiol* 1986;61:1903–1907.
- Hatcher D, Watanabe H, Ashbury T, Vincent S, Fisher J, Froese A. Mechanical performance of clinically available, neonatal, high-frequency, oscillatory-type ventilators. *Crit Care Med* 1998;26:1081–1088.
- Jouvet P, Hubert P, Isabey D, Pinquier D, Dahan E, Cloup M, Harf A. Assessment of high-frequency neonatal ventilator performances. *Intensive Care Med* 1997;23:208–213.
- Zimova-Herknerova M, Plavka R. Expired tidal volumes measured by hot-wire anemometer during high-frequency oscillation in preterm infants. *Pediatr Pulmonol* 2006;41:428–433.
- Slutsky AS, Kamm RD, Rossing TH, Loring SH, Lehr J, Shapiro AH, Ingram RH, Drazen JM. Effects of frequency, tidal volume, and lung volume on CO<sub>2</sub> elimination in dogs by high frequency (2–30 Hz), low tidal volume ventilation. *J Clin Invest* 1981;68:1475–1484.
- Kamitsuka MD, Boynton BR, Villanueva D, Vreeland PN, Frantz ID. Frequency, tidal volume, and mean airway pressure combinations that provide adequate gas exchange and low alveolar pressure during high frequency oscillatory ventilation in rabbits. *Pediatr Res* 1990;27:64–69.
- Chan V, Greenough A, Milner AD. The effect of frequency and mean airway pressure on volume delivery during high-frequency oscillation. *Pediatr Pulmonol* 1993;15:183–186.